Friday, 16 October 2026European Markets

EQUINOR And PANORO ENERGY Have A High Dividend Yield And Return On Equity In The Energy Sector.

Loading stream...

(VIANEWS) - EQUINOR (EQNR.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Energy sector.

Financial Asset Price Forward Dividend Yield Return on Equity
EQUINOR (EQNR.OL) kr364.65 3.75% 52.91%
PANORO ENERGY (PEN.OL) kr28.50 3.05% 21.81%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. EQUINOR (EQNR.OL)

3.75% Forward Dividend Yield and 52.91% Return On Equity

Equinor ASA, an energy company, engages in the exploration, production, transportation, refining, and marketing of petroleum and other forms of energy in Norway and internationally. It operates through Exploration & Production Norway; Exploration & Production International; Exploration & Production USA; Marketing, Midstream & Processing; Renewables; and Other segments. The company also transports, processes, manufactures, markets, and trades in oil and gas commodities, such as crude and condensate products, gas liquids, natural gas, and liquefied natural gas; markets and trades in power and emissions; operates refineries, terminals and processing, and power plants; and develops low carbon solutions for oil and gas. In addition, it develops carbon capture and storage projects; provides transportation solutions, including pipelines, shipping, trucking, and rail; and develops and explores for renewable energy, such as offshore wind, green hydrogen, and solar power. The company was formerly known as Statoil ASA and changed its name to Equinor ASA in May 2018. Equinor ASA was incorporated in 1972 and is headquartered in Stavanger, Norway.

Earnings Per Share

As for profitability, EQUINOR has a trailing twelve months EPS of kr62.1.

PE Ratio

EQUINOR has a trailing twelve months price to earnings ratio of 5.87. Meaning, the purchaser of the share is investing kr5.87 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 52.91%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EQUINOR's stock is considered to be overbought (>=80).

Yearly Top and Bottom Value

EQUINOR's stock is valued at kr364.65 at 16:30 EST, way below its 52-week high of kr410.95 and way above its 52-week low of kr278.70.

More news about EQUINOR.

2. PANORO ENERGY (PEN.OL)

3.05% Forward Dividend Yield and 21.81% Return On Equity

Panoro Energy ASA, an independent exploration and production company, engages in the exploration, development, and production of oil and gas properties in Africa. It holds assets in the Equatorial Guinea, Gabon, Tunisia, and South Africa. The company was incorporated in 2009 and is based in London, the United Kingdom.

Earnings Per Share

As for profitability, PANORO ENERGY has a trailing twelve months EPS of kr4.14.

PE Ratio

PANORO ENERGY has a trailing twelve months price to earnings ratio of 6.88. Meaning, the purchaser of the share is investing kr6.88 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 21.81%.

More news about PANORO ENERGY.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com